Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation

Clinical and Experimental Immunology

Volumn 118, Issue 3, 1999, Pages 465-472

  Drouet, Emmanuel ^b   Chapuis Cellier, C ^a   Bosshard, S ^a   Verniol, C ^c   Niveleau, A ^c   Touraine, J L ^a   Garnier, J L ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CNRS   (France)

^c NONE

Author keywords

Cytomegalovirus transplantation; Epstein Barr virus; Monoclonal immunoglobulins; ZEBRA

Indexed keywords

IMMEDIATE EARLY PROTEIN; IMMUNOGLOBULIN G; PARAPROTEIN; VIRUS DNA;

ARTICLE; B LYMPHOCYTE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEROLOGY; VIRUS DETECTION; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTIBODIES, VIRAL; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DNA-BINDING PROTEINS; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT REJECTION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ISOELECTRIC FOCUSING; KIDNEY TRANSPLANTATION; MONOCLONAL GAMMOPATHIES, BENIGN; SEROLOGIC TESTS; TRANS-ACTIVATORS; TUMOR VIRUS INFECTIONS; VIRAL PROTEINS; VIRUS ACTIVATION;

EID: 0032694720     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01084.x     Document Type: Article

References (46)

1. 1 Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM et al. eds. Fields virology, 3rd edn. Philadelphia: Lippincott-Raven Publishers, 1996:2397-446.
2. 2 Niedobitek G, Young LS. Epstein-Barr virus peristence and virus-associated tumours. Lancet 1994; 343:333-5.
3. 3 Hanto D. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Ann Rev Med 1995; 46:381-94.
4. 4 Rocchi G, de Felici A, Ragona G et al. Quantitative evaluation of Epstein-Barr virus-infected mononuclear peripheral blood leukocytes in infectious mononucleosis. N Engl J Med 1977; 296: 132-4.
5. 5 Crompton CH, Cheung RK, Donjon C et al. Epstein-Barr virus surveillance after renal transplantation. Transplantation 1994; 57:1182-9.
6. 6 Riddler SA, Breinig MC, McKnight JLC. Increase levels of circulating Epstein-barr virus-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of post-transplant lymphoproliferative diseases in solid-organ recipients. Blood 1994; 20:1346-53.
7. 7 Ho M, Miller G, Atchinson RW et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lympho-proliferative lesions: the role of primary infection. J Infect Dis 1985; 152:876-86.
8. 8 Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation 1988; 45:719-27.
9. 9 Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20:1346-53.
10. 10 Rinaldo CR, Carney WP, Richter BS et al. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. J Infect Dis 1980; 141:488-95.
11. 11 Nokta MA, Hassan MI, Kimberly I, et al. Human cytomegalovirus-induced immunosuppression. J Clin Invest 1996; 97:2635-41.
12. 12 Oldstone MBA. How viruses escape from cytotoxic lymphocyte: molecular parameters and players. Virology 1997; 234:179-85.
13. 13 Touraine JL. Immunoglobulin abnormalities and infectious lympho-proliferative syndrome in cyclosporine-treated transplant patients. Transplant Proc 1983; 15:2798-804.
14. 14 Radl J, Valentijn RM, Haaijman JJ et al. Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantation. Clin Immunol Immunopathol 1985; 37:98-102.
15. 15 Stanko CK, Jeefery JR, Rush DN. Monoclonal and muticlonal gammapathies after renal transplantation. Transplant Proc 1989; 21:3330-2.
16. 16 Chevallier-Greco A, Manet E, Chavrier P et al. Both Epstein-Barr virus (EBV)-encoded transacting factors EB1 and EB2 are required to activate transcription from an EBV early promoter. EMBO J 1986; 5:3243-9.
17. 17 Countryman J, Jenson H, Seibl R et al. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 1987; 61:3672-9.
18. 18 Drouet E, Chapuis-Cellier C, Garnier JL, Touraine JL. Early detection of Epstein-Barr virus infection and meaning in transplant patients. In: Touraine JL, Traeger J, Betuel H et al., eds. Cancer in transplantation prevention and treatment. Dordrecht: Kluwer Academic Publishers, 1996:207-13.
19. 19 Gan YJ, Sullivan JL, Sixbey JW. Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. J Infect Dis 1994; 170:436-9.
20. 20 Laroche C, Drouet E, Brousset P et al. Measurement by polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas. J Med Virol 1995; 46:66-74.
21. 21 Brousset P, Drouet E, Schlaifer D et al. Epstein-Barr virus (EBV) replicative gene expression in tumor cells of AIDS-related non Hodgkin's lymphoma in relation to CD4 cell number and antibody titers to EBV. AIDS 1994; 8:583-90.
22. 22 Drouet E, Colimon R, Michelson S et al. Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation. J Clin Microbiol 1995; 33:389-94.
23. 23 Mazeron MC, Colimon R, Roseto A et al. Detection of cytomegalovirus using monoclonal antibodies. Dev Biol Standard 1984; 57:287-91.
24. 24 Confavreux C, Chapuis-Cellier C, Arnaud P et al. Oligoclonal «finger-print» of cerebrospinal fluid IgG in multiple sclerosis patients is not modified following intrathecal administration of natural β-interferon. J Neurol Neurosurg Psychiatry 1986; 49:1308-12.
25. 25 Haas H, Lange A, Schlaak M. Homogeneous immunoglobulins in the sera of lung carcinoma patients receiving cytotoxic chemotherapy-detection with the use of isoelectric focusing and immunoblotting. Clin Exp Immunol 1987; 70:630-9.
26. 26 Deteix P, Chapuis-Cellier C, Ghais Z et al. Systematic survey of immunoglobulin abnormalities: frequency, and evolution in organ transplant recipients. Transplant Proc 1985; 17:2651-4.
27. 27 Michelson S. Mechanisms of immunosuppression by human cytomegalovirus. CMV-related immunopathology. Scholz M, Rubenau MF, Doerr HW et al., eds. Monogr Virol Basel: Karger, 1998:12-28.
28. 28 Rooney CA, Loftin SK, Holladay MS et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative diseases. Br J Haematol 1995; 89:98-103.
29. 29 Green M, Reyes J, Jabbour N et al. Use of quantitative PCR to predict onset of Epstein-Barr viral infection and post-transplant lymphoproliferative disease after intestinal transplantation in children. Transplant Proc 1996; 28:2759-60.
30. 30 Schepers A, Pich D, Hammerschmidt W. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of EBV. EMBO J 1993; 12:3921-9.
31. 31 Schepers A, Pich D, Hammerschmidt W. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLFI. Virology 1996; 220:367-76.
32. 32 Tedeschi R, Foong YT, Cheng HM et al. The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol 1995; 76:1393-400.
33. 33 Peest D, Schaper B, Nashan B et al. High incidence of homogeneous Igs in patients after liver or heart transplantation. Transplantation 1988; 46:389-93.
34. 34 Garnier JL, Berger F, Betuel H et al. Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation. Nephrol Dial Transplant 1989; 4:818-23.
35. 35 Hanto DW, Birkenbach M, Frizzera G et al. Confirmation of the heterogeneity of post-transplant Epstein-Barr virus associated B cell proliferation by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47:458-64.
36. 36 Preiksaitis JK, Diaz-Mitoma F, Mirzayans F et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac tranplant patients. Relationship to immunosuppressive therapy, serologic responses and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166:986.
37. 37 Gerritsen EJA, Van Tol MJD, Lankester AC et al. Immunoglobulin levels and monoclonal gammapathies in children after bone marrow transplantation. Blood 1993; 82:3493-502.
38. 38 Hornef MW, Bein G, Fricke L et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection and rejection episodes in renal transplant recipients. Transplantation 1996; 60:474-80.
39. 39 Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176:1462-7.
40. 40 Bancel J, Plotnicky H, Rousset F, Touraine JL, Touraine F. Diagnosis and management of overimmunosuppression after transplantation. In: Touraine JL, Traeger J, Betuel H et al., eds. Transplantation and clinical immunology, evaluation and monitoring in transplantation. Amsterdam: Elsevier, 1992:541-7.
41. 41 Hornef MW, Wagner HJ, Fricke L et al. Immunocytochemical detection of Epstein-Barr virus antigens in peripheral B lymphocytes after renal transplantation. Transplantation 1995; 59:138-40.
42. 42 Michelson S, Alcami J, Kim SJ et al. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor β1 (TGF β1). J Virol 1994; 68:5730-7.
43. 43 Mathew A, Cheng HM, Sam CK et al. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol Immunother 1994; 38:68-70.
44. 44 Drouet E, Brousset P, Fares F et al. High Epstein-Barr virus (EBV) serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol 1999; 57:383-9.
45. 45 Farrell P, Rowe D, Kouzarides JT. Epstein-Barr virus BZLF1 transactivator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 1989; 8:127-32.
46. 46 Gstaiger M, Hovens C, Georgiev O et al. BZLF1 (ZEBRA, Zta) protein of Epstein-Barr virus selected in a yeast one-hybrid system by binding to a consensus in the IgG intronic enhancer: a role in immunoglobulin expression. Biol Chem 1996; 377:669-73.